RecruitingNCT06763289

Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection

Comparison Between Multi-omics Models Including DNA Methylation in CfDNA, Quantitative Determination of Epstein-Barr Virus Nucleic Acid and Serological Double Antibody Detection in Early Screening of Nasopharyngeal Carcinoma


Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Enrollment

700 participants

Start Date

Dec 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the performance differences among multi-omics models such as nasopharyngeal carcinoma-specific DNA methylation and fragmentome in the multi-cancer early screening model and the clinically routinely conducted Epstein-Barr virus (EBV) nucleic acid quantification (EBV DNA) test and serological double antibody (double antibodies of EBNA1-IgA and VCA-IgA) test. It suggests that compared with EBV DNA quantification and double antibody tests, in patients with nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false negatives, improve sensitivity, and increase the detection rate of early-stage nasopharyngeal carcinoma; in patients without nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false positives, improve specificity, and avoid unnecessary over-diagnosis.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing three different blood-based screening tests for early detection of nasopharyngeal carcinoma (a cancer of the back of the nose and throat): cell-free DNA methylation analysis, EBV DNA testing, and antibody testing. This is a research/screening study, not a treatment trial. **You may be eligible if...** - You are between 40 and 74 years old - You have been clinically or pathologically diagnosed with cancer (for the case group) - You have NOT yet started any cancer treatment (surgery, radiation, chemotherapy, immunotherapy, etc.) - You are able to give written consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have another type of cancer at the same time - You have had a severe recent infection or high fever in the last 14 days - You have had an organ transplant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06763289


Related Trials